醫思醫療(02138.HK)旗下醫療中心參與港府疫苗接種計劃
醫思醫療(02138.HK)公布,集團13名從業醫生已經註冊參加香港政府的新冠病毒疫苗接種計劃,旗下位處香港的醫療中心會為五個優先組別的人士注射科興生物「CoronaVac」疫苗。
五個優先組包括 60 歲或以上人士(陪同 70 歲或以上人士的最多兩名護理人員)、醫療機構人員和參與對抗流行病的工作人員、老年人/殘疾人士院舍的入住人士和工作人員、維持重要公共服務的人員以及從事跨境相關工作的人員。
集團表示,一直有參與提供政府認可的新冠病毒檢測,並提供各種新冠病毒相關檢測服務及遠程諮詢服務,將與香港政府積極合作提供有關新冠病毒疫苗接種服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.